Involvement of uric acid transporters in alteration of serum uric acid level by angiotensin II receptor blockers

Pharmaceutical Research

Volumn 25, Issue 3, 2008, Pages 639-646

  Sato, Masanobu ^a   Iwanaga, Takashi ^a   Mamada, Hideaki ^a   Ogihara, Toshio ^b   Yabuuchi, Hikaru ^c   Maeda, Tomoji ^a   Tamai, Ikumi ^a  

^a TOKYO UNIVERSITY OF SCIENCE   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c GenoMembrane Inc ^*  (Japan)

Author keywords

Angiotensin II receptor blockers; Kidney; MRP4; OAT; Uric acid transporter

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN; ESTRONE SULFATE; LOSARTAN; MULTIDRUG RESISTANCE PROTEIN 4; OLMESARTAN; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 3; ORGANIC ANION TRANSPORTER 4; PRATOSARTAN; TELMISARTAN; UNCLASSIFIED DRUG; URIC ACID; VALSARTAN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; HUMAN; HUMAN TISSUE; IC 50; MEMBRANE VESICLE; NONHUMAN; NUCLEOTIDE SEQUENCE; OOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; URIC ACID BLOOD LEVEL; XENOPUS;

EID: 40549090278     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-007-9401-6     Document Type: Article

References (26)

1. 1. M. H. Alderman H. Cohen S. Madhavan S. Kivlighn 1999 Serum uric acid and cardiovascular events in successfully treated hypertensive patients Hypertension 34 144 150 10406838 1:STN:280:DyaK1MzjsFOhsg%3D%3D M. H. Alderman, H. Cohen, S. Madhavan, and S. Kivlighn. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 34:144–150 (1999).
2. 2. P. Verdecchia G. Schillaci G. Reboldi S. C. Santeusanio C. Porcellati 2000 Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study Hypertension 36 1072 1078 11116127 1:CAS:528:DC%2BD3MXitlSntQ%3D%3D P. Verdecchia, G. Schillaci, G. Reboldi, S. C. Santeusanio, C. Porcellati, and P. Brunetti. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension 36:1072–1078 (2000).
3. 3. A. J. Manolis E. Grossman B. Jelakovic A. Jacovides D. C. Bernhardi W. J. Cabrera L. A. Watanabe J. Barragan N. Matadamas A. Mendiola K. S. Woo J. R. Zhu A. D. Mejia T. Bunt T. Dumortier R. D. Smith 2000 Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators Clin. Ther. 22 1186 1203 11110230 10.1016/S0149-2918(00)83062-3 1:CAS:528:DC%2BD3cXosFygtrY%3D A. J. Manolis, E. Grossman, B. Jelakovic, A. Jacovides, D. C. Bernhardi, W. J. Cabrera, L. A. Watanabe, J. Barragan, N. Matadamas, A. Mendiola, K. S. Woo, J. R. Zhu, A. D. Mejia, T. Bunt, T. Dumortier, and R. D. Smith. Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators. Clin. Ther. 22:1186–1203 (2000).
4. 4. W. J. Elliott D. A. Calhoun P. T. DeLucca L. P. Gazdick D. E. Kerns R. K. Zeldin 2001 Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial Clin. Ther. 23 1166 1179 11558856 10.1016/S0149-2918(01)80099-0 1:CAS:528:DC%2BD3MXnt1SntLg%3D W. J. Elliott, D. A. Calhoun, P. T. DeLucca, L. P. Gazdick, D. E. Kerns, and R. K. Zeldin. Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial. Clin. Ther. 23:1166–1179 (2001).
5. 5. M. Nakashima T. Uematsu K. Kosuge M. Kanamaru 1992 Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects Eur. J. Clin. Pharmacol. 42 333 335 1577054 10.1007/BF00266358 1:CAS:528:DyaK38XktVSmsLc%3D M. Nakashima, T. Uematsu, K. Kosuge, and M. Kanamaru. Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur. J. Clin. Pharmacol. 42:333–335 (1992).
6. 6. M. Burnier B. Rutschmann J. Nussberger J. Versaggi S. Shahinfar B. Weaber 1993 Brunner salt-dependent renal effects of an angiotensin II antagonist in healthy subjects Hypertension 22 339 347 8349327 1:CAS:528:DyaK3sXms1aitbk%3D M. Burnier, B. Rutschmann, J. Nussberger, J. Versaggi, S. Shahinfar, B. Weaber, and H.R. Brunner salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension 22:339–347 (1993).
7. 7. J. P. Fauvel S. Velon N. Berra N. Pozet O. Madonna P. Zech M. Laville 1996 Effects of losartan on renal function in patients with essential hypertension J. Cardiovasc. Pharmacol. 28 259 263 8856482 10.1097/00005344-199608000-00012 1:CAS:528:DyaK28XkvFGksbc%3D J. P. Fauvel, S. Velon, N. Berra, N. Pozet, O. Madonna, P. Zech, and M. Laville. Effects of losartan on renal function in patients with essential hypertension. J. Cardiovasc. Pharmacol. 28:259–263 (1996).
8. 8. R. W. Rundles 1985 The development of allopurinol Arch. Intern. Med. 145 1492 1503 3896181 10.1001/archinte.145.8.1492 1:CAS:528:DyaL2MXltFGnu74%3D R. W. Rundles. The development of allopurinol. Arch. Intern. Med. 145:1492–1503 (1985).
9. 9. D. A. Sica A. C. Schoolwerth 2000 Chapter 16, Renal handling of organic anions and cations: excretion of uric acid B. M. Brenner The Kidney 6 Saunders Philadelphia 680 700 D. A. Sica and A. C. Schoolwerth. Chapter 16, Renal handling of organic anions and cations: Excretion of uric acid. In B. M. Brenner (ed.), The Kidney, 6th edn, Saunders, Philadelphia, 2000, pp. 680–700.
10. 10. M. A. Hediger R. J. Johnson H. Miyazaki H. Endou 2005 Molecular physiology of urate transport Physiology 20 125 133 15772301 10.1152/physiol.00039.2004 1:CAS:528:DC%2BD2MXjs1Ontrk%3D M. A. Hediger, R. J. Johnson, H. Miyazaki, and H. Endou. Molecular physiology of urate transport. Physiology 20:125–133 (2005).
11. 11. A. Enomoto H. Kimura A. Chairoungdua Y. Shigeta P. Jutabha S. H. Cha M. Hosoyamada M. Takeda T. Sekine T. Igarashi H. Matsuo Y. Kikuchi T. Oda K. Ichida T. Hosoya K. Shimokata T. Niwa Y. Kanai H. Endou 2002 Molecular identification of a renal urate anion exchanger that regulates blood urate levels Nature 417 447 452 12024214 1:CAS:528:DC%2BD38XjvVersrs%3D A. Enomoto, H. Kimura, A. Chairoungdua, Y Shigeta, P. Jutabha, S. H. Cha, M Hosoyamada, M. Takeda, T. Sekine, T. Igarashi, H. Matsuo, Y. Kikuchi, T. Oda, K. Ichida, T. Hosoya, K. Shimokata, T. Niwa, Y. Kanai, and H. Endou. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 417:447–452 (2002).
12. 12. Y. Hagos D. Stein B. Ugele G. Burckhardt A. Bahn 2007 Human renal organic anion transporter 4 operates as an asymmetric urate transporter J. Am. Soc. Nephrol. 18 430 437 17229912 10.1681/ASN.2006040415 1:CAS:528:DC%2BD2sXit12jtbg%3D Y. Hagos, D. Stein, B. Ugele, G. Burckhardt, and A. Bahn. Human renal organic anion transporter 4 operates as an asymmetric urate transporter. J. Am. Soc. Nephrol. 18:430–437 (2007).
13. 13. K. Icida M. Hosoyamada H. Kimura M. Takeda Y. Utsunomiya T. Hosoya H. Endou 2003 Urate transport via human PAH transporter hOAT1 and its gene structure Kidney Int. 63 143 155 10.1046/j.1523-1755.2003.00710.x K. Icida, M. Hosoyamada, H. Kimura, M. Takeda, Y. Utsunomiya, T. Hosoya, and H. Endou. Urate transport via human PAH transporter hOAT1 and its gene structure. Kidney Int. 63:143–155 (2003).
14. 14. S. H. Cha T. Sekine J. Fukushima Y. Kanai Y. Kobayashi T. Goya H. Endou 2001 Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney Mol. Pharmacol. 59 1277 1286 11306713 1:CAS:528:DC%2BD3MXjt1aqtbo%3D S. H. Cha, T. Sekine, J. Fukushima, Y. Kanai, Y. Kobayashi, T. Goya, and H. Endou. Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol. Pharmacol. 59:1277–1286 (2001).
15. 15. R. A. M. H. Aubel van P. H. E. Smeets J. J. M. W. Heuvel van den F. G. M. Russel 2004 Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites Am. J. Physiol. Renal. Physiol. 288 F327 F333 15454390 10.1152/ajprenal.00133.2004 R. A. M. H. van Aubel, P. H. E. Smeets, J. J. M. W. van den Heuvel, and F. G. M. Russel. Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites. Am. J. Physiol. Renal. Physiol. 288:F327–F333 (2004).
16. 16. N. Ishiguro A. Saito K. Yokoyama M. Morikawa T. Igarashi I. Tamai 2005 Transport of the dopamine D2 agonist pramipexole by rat organic cation transporters OCT1 and OCT2 in kidney Drug Metab. Dispos. 33 495 499 15640376 10.1124/dmd.104.002519 1:CAS:528:DC%2BD2MXjtFequ7c%3D N. Ishiguro, A. Saito, K. Yokoyama, M. Morikawa, T. Igarashi, and I Tamai. Transport of the dopamine D2 agonist pramipexole by rat organic cation transporters OCT1 and OCT2 in kidney. Drug Metab. Dispos. 33:495–499 (2005).
17. 17. A. Tsuji A. Sakata I. Tamai 1997 Tissue distribution of the multidrug-resistance gene product P-glycoprotein and its physiological function Nippon Rinsho 55 1059 1063 9155153 1:STN:280:ByiA3c%2FgsVU%3D A Tsuji, A. Sakata, and I Tamai. Tissue distribution of the multidrug-resistance gene product P-glycoprotein and its physiological function. Nippon Rinsho 55:1059–1063 (1997).
18. 18. R. Ohashi I. Tamai H. Yabuuchi J. Nezu A. Oku Y. Sai M. Shimane A. Tsuji 1999 Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance J. Pharmacol. Exp. Ther. 291 778 784 10525100 1:CAS:528:DyaK1MXntFChurs%3D R. Ohashi, I Tamai, H. Yabuuchi, J. Nezu, A. Oku, Y. Sai, M. Shimane, and A. Tsuji. Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J. Pharmacol. Exp. Ther. 291:778–784 (1999).
19. 19. T. Iwanaga M. Sato T. Maeda T. Ogihara I. Tamai 2007 Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter J. Pharmacol. Exp. Ther. 320 211 217 17043154 10.1124/jpet.106.112755 1:CAS:528:DC%2BD2sXjsFCjtg%3D%3D T. Iwanaga, M. Sato, T. Maeda, T. Ogihara, and I Tamai. Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. J. Pharmacol. Exp. Ther. 320:211–217 (2007).
20. 20. M. Hosoyamada T. Sekine Y. Kanai H. Endou 1999 Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney Am. J. Physiol. 276 F122 F128 9887087 1:CAS:528:DyaK1MXntlCntA%3D%3D M. Hosoyamada, T. Sekine, Y. Kanai, and H. Endou. Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. Am. J. Physiol. 276:F122–F128 (1999).
21. 21. E. R. Liman J. Tytgat P. Hess 1992 Subunit stoichiometry of a mammalian K + channel determined by construction of multimeric cDNAs Neuron 9 861 871 1419000 10.1016/0896-6273(92)90239-A 1:CAS:528:DyaK3sXjsVOisw%3D%3D E. R. Liman, J. Tytgat, and P. Hess. Subunit stoichiometry of a mammalian K + channel determined by construction of multimeric cDNAs. Neuron 9:861–871 (1992).
22. 22. T. Iwanaga D. Kobayashi M. Hirayama T. Maeda I. Tamai 2005 Involvement of uric acid transporter in increased renal clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone Drug Metab. Dispos. 33 1791 1795 16135657 1:CAS:528:DC%2BD2MXht1ygu7rP T. Iwanaga, D. Kobayashi, M. Hirayama, T. Maeda, and I. Tamai. Involvement of uric acid transporter in increased renal clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone. Drug Metab. Dispos. 33:1791–1795 (2005).
23. 23. M. Tsuda-Tsukimoto T. Maeda T. Iwanaga T. Kume I. Tamai 2006 Characterization of hepatobiliary transport systems of a novel α4β1/α4β7 dual antagonist, TR-14035 Pharm. Res. 23 2646 2656 16969695 10.1007/s11095-006-9102-6 1:CAS:528:DC%2BD28XhtFKgu7nK M. Tsuda-Tsukimoto, T. Maeda, T. Iwanaga, T. Kume, and I Tamai. Characterization of hepatobiliary transport systems of a novel α4β1/α4β7 dual antagonist, TR-14035. Pharm. Res. 23:2646–2656 (2006).
24. 24. M. Rius A. T. Nies J. Hummel-Eisenbeiss G. Jedlitschky D. Keppler 2003 Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane Hepatology 38 374 384 12883481 10.1053/jhep.2003.50331 1:CAS:528:DC%2BD3sXmvFSmtbk%3D M. Rius, A. T. Nies, J. Hummel-Eisenbeiss, G. Jedlitschky, and D. Keppler. Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Hepatology. 38:374–384 (2003).
25. 25. F. Yamashita H. Ohtani N. Koyabu F. Ushigome H. Satoh H. Murakami T. Uchiumi T. Nakamura M. Kuwano M. Tsujimoto Y. Sawada 2006 Inhibitory effect of angiotensin II receptor antagonists and leukotriene receptor antagonists on the transport of human organic transporter 4 J. Pharm. Pharmacol. 58 1499 1505 17132213 10.1211/jpp.58.11.0011 1:CAS:528:DC%2BD2sXksVKmtrY%3D F. Yamashita, H. Ohtani, N. Koyabu, F. Ushigome, H. Satoh, H. Murakami, T. Uchiumi, T. Nakamura, M. Kuwano, M. Tsujimoto, and Y. Sawada. Inhibitory effect of angiotensin II receptor antagonists and leukotriene receptor antagonists on the transport of human organic transporter 4. J. Pharm. Pharmacol. 58:1499–1505 (2006).
26. 26. H. Uchino I. Tamai K. Yamashita Y. Minemoto Y. Sai H. Yabuuchi K. Miyamoto E. Takeda A. Tsuji 2000 p-Aminohippuric acid transport at renal apical membrane mediated by human inorganic phosphate transporter NPT1 Biochem. Biophys. Res. Commun. 270 254 259 10733936 10.1006/bbrc.2000.2407 1:CAS:528:DC%2BD3cXhvFClsrw%3D H. Uchino, I Tamai, K. Yamashita, Y. Minemoto, Y. Sai, H. Yabuuchi, K. Miyamoto, E. Takeda, and A Tsuji. p-Aminohippuric acid transport at renal apical membrane mediated by human inorganic phosphate transporter NPT1. Biochem. Biophys. Res. Commun. 270:254–259 (2000).